Regeneron Pharmaceuticals Inc. buy JPMorgan Chase & Co.
Summary
This prediction is currently active. The prediction currently has a performance of 16.62%. Dividends of €3.58 are taken into consideration when calculating the performance. This prediction currently runs until 31.03.26. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | 1.867% | 1.867% |
| iShares Core DAX® | -3.809% | -1.472% |
| iShares Nasdaq 100 | 0.487% | 2.215% |
| iShares Nikkei 225® | -4.418% | 4.971% |
| iShares S&P 500 | 0.251% | 1.225% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by JPMorgan_Chase___Co_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
02.02.26
02.02.27
12:08
Regeneron Pharmaceuticals Inc.
09.06.25
09.06.26
12:08
Regeneron Pharmaceuticals Inc.
24.10.24
24.10.25
25.10.25
Regeneron Pharmaceuticals Inc.
02.08.24
02.08.25
03.08.25
Regeneron Pharmaceuticals Inc.
17.06.24
17.06.25
18.06.25

